期刊文献+

聚乙二醇化重组集成α干扰素在食蟹猴长期毒性中结合抗体和中和抗体的活性

Activities of Serum Binding Antibody and Neutralizing Antibody on the Cynomolgus Undergoing Long-term Toxicity Study with Polyglycol Recombinant Consensus Interferon α
下载PDF
导出
摘要 研究了食蟹猴皮下注射聚乙二醇化重组集成α干扰素(代号PEG-SA)低、中、高剂量(10,30,90μg/kg及对照组)1次/7 d,共180 d后血清中第15,29,43,57,71,92,113,134,162,180 d及停药后30 d的结合抗体及中和抗体滴度。结合抗体测定采用的是间接ELISA法,中和抗体测定采用的是细胞病变抑制法。结合抗体滴度以OD值大于阴性对照组OD值2.1倍为阳性。中和抗体活性的产生以保护50%细胞免受病毒侵犯为判断依据,即50%细胞病变表明产生中和抗体。结果表明,两者活性均在57 d到达高峰,停药后结合抗体和中和抗体活性减弱或消失,中高剂量组抗体活性高于同时段低剂量组活性。PEG-SA皮下注射后,可诱导食蟹猴产生结合抗体及中和抗体,二者活性具有剂量相关性。 To study the titer of binding antibody and neutralizing antibody about m.fascicularis' serum after subcutaneous injected 1/7d,a total of 180 days with low,middile and high-dose(10ug/kg,30ug/kg,90ug/kg and control group)pegylated of recombinant interferon alfacon(codenamed PEG-SA) for 15th,29th,43th,57th,71th,92th,113th,134th,162th and 180th and 30th after drug withdrawal.Methods:Binding antibody was measured by the indirect ELISA.Neutralizing antibody was measured by the cytopathic effect inhibition assay.Judgments based on:binding antibody titers with OD values greater than the negative control group's 2.1 times as positive.Production of neutralizing antibody activity of protect 50% cells from virus encroachment as a judgment.50% cells has pathological change provided produce neutralizing antibody.Result:On the 57th,both binding antibody and neutralizing antibody of activity reach the peak,and their to diminish or disappear after withdrawal.Antibody activity in the middle and high-dose group is higher than the low-dose group at the same time.Conclusion: Subcutaneous injection with PEG-SA,may induce m.fascicularis produced binding antibody and neutralizing antibody,both titer of them has dose-dependent.
机构地区 重庆理工大学
出处 《重庆理工大学学报(自然科学)》 CAS 2010年第4期26-29,共4页 Journal of Chongqing University of Technology:Natural Science
基金 国家"重大新药创制"科技重大专项资助项目(2009zx09102-251)
关键词 聚乙二醇化重组集成干扰素 ELISA 细胞病变抑制法 食蟹猴 中和抗体 PEG-SA ELISA cytopathic-effect inhibition assay m.fascicularis neutralizing
  • 相关文献

参考文献7

二级参考文献58

  • 1[1]Antonelli G,Gurrenti M,Turriziani O,et al.Neutralizing antibodies to interferon-α:relative frequency in patients treated with different interferon preparations[J].J Infect Dis,1991,163:882.
  • 2[2]周海钧主译.ICH药品注册国际技术要求[M].北京:人民卫生出版社,2001:121.
  • 3[3]Antonelli G,Giannelli G,Currenti M,et al.Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy[J].Clin Exp Immunol,1996,104(3):384.
  • 4[4]Milella M,Antonelli G,Santantonio T,et al.Treatment with natural IFN of hepatitis C patients with orwithout antibodies to recombinant IFN[J].Hepatogastroenterology.1995,42(3):201.
  • 5[5]Milella M,Antonelli G,Santantonio T,et al.Neutralizing antibody to re-combinant alpha interferon and response to therapy in chronic hepatitis C virus infection[J].Liver,1993,13(3):146.
  • 6[8]Ozes ON,Reiter Z,Klein S,et al.A comparison of interferon-con 1 with natural recombinant interferons-α:antiviral,antiproliferative,and natural killer-induceing activities[J].J Interferon Res,1992,12(1):55.
  • 7[9]Tong MJ,Blatt LM,Resser KJ,et al.Treatment of chronic hepatitis C virus infection with recombinant consensus interferon[J].J Interferon and Cytokine Res,1998,18(1):81.
  • 8Porres JC, Carreno V, Ruiz M, et al. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatol, 1989, 8: 351-357.
  • 9Lok AS, Lai CL, Leung EK. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology, 1990,12: 1266-1270.
  • 10Leroy V, Baud M, de Traversay C, et al. Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol, 1998, 28: 375-381.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部